Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex in High-Risk ALL After alloHSCT
NCT06735690Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2025
- Primary completion
- Mar 2029
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19-CAR CMV-specific T-lymphocytes and Triplex in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by City of Hope. Primary endpoints: Incidence of adverse events and Dose-limiting toxicities. Started Dec 2025; status: recruiting.
02
Drugs
anti-CD19-CAR CMV-specific T-lymphocytesTriplex
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06735690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735690.